Harness Biotech Stock Volatility with an Options StrategyCompanies / BioTechAug 13, 2015 – 10:27 PM GMTBy: TLSReportVolatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That’s the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names […]
With many investors starting to get more scared about China, scared about Europe and even scared about the coming interest rate hike cycle from the Federal Reserve, some smart money investors may be trying to figure out which stocks have already been heavily discounted to factor in bad news already. It may be impossible to ever know if a true […]
Related FOLDMid-Morning Market Update: Markets Gain; Finish Line Beats Q1 ViewsMorning Market GainersRelated IPXLUS Stock Futures Signal Higher Start On Wall StreetImpax Announces Sale of Daraprim to Turing Pharmaceuticals AG , ~$55MAquinox’s Shares Shoot Up, Bladder Pain Drug in Focus(Zacks)In a recent report, analysts at Leerink shared their views on a ton of biotech stocks. Here is a look at […]
Related ICPTCNBC’s Meg Tirrel Speculates About Gilead’s New AcquisitonHow Wedbush’s Liana Moussatos Is Trading These Biopharma StocksShaken, Not Stirred: Is The ‘Biotech Bubble’ Beginning To Burst?(Seeking Alpha)Related Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platformShort-Sellers Betting Against These BiotechsSarepta Posts Narrower-than-Expected Loss in […]
Related AMGNSocial Media Beat: What The Crowd & Experts Think Of Oil, Biotech & LinkedInStocks Hitting 52-Week HighsAre You Ready For A Pullback BIIB AMGN GILD CELG UTHR JAZZ GOOG FB NFLX APA APC EOG PANW DO RIG(Marketfy Insights)Related CELG5 Biotechs With Catalysts Coming This WeekIs More M&A On The Way For Large-Cap Biotechs?Are You Ready For A Pullback BIIB […]
First, the scoreboard:Dow: 17,419.75, -120.72, (-0.69%)
S&P 500: 2,083.56, -16.28, (-0.78%)
Nasdaq: 5,056.44, -83.50, (-1.62%)
And now, the top stories on Thursday:Media stocks plunged. Viacom shares dived more than 21% after the company reported lower-than-expected ad revenues from its cable business. The stocks were shaken up by concerns about the cable industry amid the rise of pay TV. Comcast, Time Warner, and 21st Century Fox also declined […]
By Ben LevisohnIn a note this morning, BofA Merrill Lynch’s Christina Giannini and team note that the risk for big-cap biotech stocks–think Gilead Sciences (GILD) and Biogen (BIIB)–and small-cap biotech stocks–everything else–are quite different. They explain:
Associated Press
Biotech is now more passive than actively managed: Perhaps due to the difficulty picking stocks within such an idiosyncratic sector given the complicated science […]
Several major biotech companies like Biogen (BIIB – Analyst Report), AbbVie (ABBV – Analyst Report), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons – although the company’s earnings were better-than-expected, revenues missed expectations.With the company saying that it is cutting its outlook based on revised expectations […]
Related TEVATeva Still A ‘Must-Own’ Stock, Worth $86Benzinga’s Top UpgradesWeekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA(GuruFocus)Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) surged to new 52-week highs of $69.42 on Monday after the company announced its acquisition of Allergan PLC (NYSE: AGN)’s Generics segment for a total consideration of $40.5 billion.Shares of Allergan also spiked to new […]
By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]
